Oncoscience


2024 Press Releases

A Very Long, Winding Road: Developing Novel Therapeutics for Metastatic Tumors


FOR IMMEDIATE RELEASE
2024-02-23

“Given that the MET inhibitor capmatinib caused a remarkable response in Dr. Blagosklonny, a pertinent question remains as to why he was not treated with ‘preemptive drug combinations’ [...]”



BUFFALO, NY - February 23, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on February 9, 2024, entitled, “A very long and winding road: developing novel therapeutics for metastatic tumors.”

In this editorial, researcher Paul Dent from the Department of Biochemistry and

... continue reading >>

IPIAD: An Augmentation to Standard Treatment of PDAC Using Five Repurposed Drugs


FOR IMMEDIATE RELEASE
2024-02-09

“This paper presents the rationale for adding five already approved and marketed generic drugs from general medical practice to the current standard current first line chemotherapy for pancreatic ductal adenocarcinoma (PDAC).”



BUFFALO, NY - February 9, 2024 – A new research perspective was recently published in Oncoscience (Volume 11) on February 7, 2024, entitled, “IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed

... continue reading >>

Dr. Blagosklonny's Battle With Cancer (Part 1)


FOR IMMEDIATE RELEASE
2024-01-22

“Diagnosed with numerous metastases of lung cancer in my brain in January 2023, I felt compelled to accomplish a mission.”



BUFFALO, NY- January 22, 2024 – On January 3, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new brief report in Oncoscience (Volume 11), entitled, “My battle with cancer. Part 1.

“In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I... continue reading >>

Mutational Signatures of Cancer: Can Passengers Set a Direction for Prognosis?


FOR IMMEDIATE RELEASE
2024-01-19

“[...] mutational signatures are not only genomic noise of passenger mutations, but they provide etiological and biological information on carcinogenesis.”



BUFFALO, NY- January 19, 2024 – A new editorial paper was recently published in Oncoscience (Volume 10), by researcher Peeter Karihtala from the University of Helsinki and University Hospital Comprehensive Cancer Center, entitled, “The mutational signatures of cancer: can passengers set a direction for prognosis?

In the early

... continue reading >>

Pazopanib in EWSR1-NFATC2 Translocation-associated Bone Sarcoma


FOR IMMEDIATE RELEASE
2024-01-12

“Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma.”



BUFFALO, NY- January 12, 2024 – A new case report was recently published in Oncoscience (Volume 10) on September 20, 2023, entitled, “Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma.”

Pazopanib, a multi-kinase VEGF inhibitor, is currently FDA approved for advanced renal cell carcinoma and advanced

... continue reading >>

Lipiodol: From Intrusion to Exile From the Tumor Microenvironment


FOR IMMEDIATE RELEASE
2024-01-05

“[...] this study proposed that the size of the tumor [...] and lipiodol washout rate could predict the outcome of cTACE in patients with metastatic liver tumors.”



BUFFALO, NY- January 5, 2024 – An editorial paper was recently published in Oncoscience (Volume 10) on August 17, 2023, entitled, “Lipiodol: from intrusion until exile from the tumor microenvironment.”

In this new editorial, researchers Sheena Anand, Jean-François Geschwind, Vahid Etezadi, and Nariman Nezami from the Univer

... continue reading >>